Predicting response to hormone treatment in endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether biopsy test results can help predict how well hormone therapy will work for advanced or recurrent endometrial cancer. It may help doctors choose the most effective hormonal treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that is advanced (stage III/IV) or has come back (recurrent)
- A treatment plan includes starting hormone therapy for your endometrial cancer
- You had a biopsy taken within the last 120 days before starting hormone therapy
- You have not had any other cancer treatment between the biopsy and starting hormone therapy
- You do not have endometrial sarcoma (or a specific related tumor type called endometrial stromal cell sarcoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
This trial is testing whether a computer model powered by artificial intelligence can better predict outcomes for people with endometrial cancer or related conditions. It uses patient data and tissue samples to see if the model can help doctors choose the best care.
This study is looking at whether certain patient information can help predict if HR+/HER2- early breast cancer will come back. If you have had surgery and hormone therapy, your data might help improve future care.
Hear when a new Endometrial Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.